
Nyxoah SA (NYXH) Stock Forecast & Price Target
Nyxoah SA (NYXH) Analyst Ratings
Bulls say
Nyxoah is constructive fundamentally because its U.S. rollout continues to build through measurable operating momentum, with 80 additional trained surgeons, 53 activated accounts, 447 patients under active prior authorization, and a 29% sequential increase in U.S. growth, suggesting the recent revenue guide reset reflects timing rather than demand deterioration. The company also has a meaningful regulatory catalyst in motion, as it submitted its PMA supplement for CCC after ACCCESS met both co-primary efficacy endpoints with a 77.2% 12-month AHI responder rate and zero device- or procedure-related SAEs, which could expand the addressable OSA population by roughly 25-30%. Financially, Q2 net revenue of €7.7M was in line with expectations and FY26 guidance of €36-40M was reiterated, while Genio 2.1 approval, ongoing sales hiring, and the planned 2027 reimbursement pathway support a longer-term commercialization thesis.
Bears say
Nyxoah is facing a weakening fundamental setup after pre-announcing 3Q26 net revenue of €9.2M versus FactSet consensus of €9.9M and cutting full-year 2026 revenue guidance to €33-35M from €36-40M, signaling softer-than-expected commercialization momentum. The company still depends on a cash-burn-heavy model to scale its Genio system against the market leader Inspire Medical Systems, which leaves it vulnerable to adoption risk and the possibility of needing additional capital. In addition, regulatory uncertainty around the ACCCESS study and the fact that valuation still implies 1.9x 2027 EV/revenue and 2.8x 2028 EV/revenue, even at a 54% discount to peers, support a cautious outlook.
This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.
Nyxoah SA (NYXH) Analyst Forecast & Price Prediction
Start investing in Nyxoah SA (NYXH)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Nyxoah SA (NYXH) Forecast
Nyxoah SA (NYXH) Analyst Forecast & Price Prediction
Start investing in Nyxoah SA (NYXH)
Order type
Buy in
Order amount
Est. shares
0 shares